About our research group/lab
Our research
Pharmacogenetics
Research of the group has a focus on the value and subsequent clinical implementation of pharmacogenetics. Current topics are:
- Oncology (capecitabine, irinotecan, paclitaxel, docetaxel, tamoxifen, nivolumab, pembrolizumab)
- Immunosuppressants (tacrolimus, cyclosporine, MMF)
- Opioids (morphine, tramadol, propofol, oxycodone).
- Antidepressants/antipsychotics
Opioid dependency
Very recent, a 16 gene panel has been introduced to the FDA to be able to predict opioid dependency. We are investigating the clinical validity of this test, and its implementation to control the widespread opioid dependency in The Netherlands. For this, we have a close and exclusive collaboration with a US based company.
Cell free DNA
A new, non-invasive and sensitive biomarker approach is to make use of the detection of DNA variants in blood: cell free DNA analysis. We investigate this approach in three research lines:
- NSCLC. Analysis of EGFR T790M, L858R, exon19 skipping and C797S mutations can guide decisions on the use of osimertinib.
- Prostate cancer. Analysis of exosomal RNA of the AR-V7 transcript has added value in the treatment of castrate resistant prostate cancer
- Heart/kidney transplantation. Monitoring of graft rejection by using cfDNA techniques.
Prostate cancer & Cardiac Biomarkers
This research is focusing on new markers for the early detection of prostate cancer (collaboration with Dept. Urology, Prof. Chris Bangma) and new markers for the early detection of acute myocardial infarction (collaboration with Dept. Cardiology, Prof. Eric Boersma).Key Publications
1. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis.. Henricks LM(1), Lunenburg CATC(2), de Man FM(3), Meulendijks D(4), Frederix GWJ(5), Kienhuis E(3), Creemers GJ(6), Baars A(7), Dezentjé VO(8), Imholz ALT(9), Jeurissen FJF(10), Portielje JEA(11), Jansen RLH(12), Hamberg P(13), Ten Tije AJ(14), Droogendijk HJ(15), Koopman M(16), Nieboer P(17), van de Poel MHW(18), Mandigers CMPW(19), Rosing H(20), Beijnen JH(21), Werkhoven EV(22), van Kuilenburg ABP(23), van Schaik RHN(24), Mathijssen RHJ(3), Swen JJ(25), Gelderblom H(2), Cats A(26), Guchelaar HJ(25), Schellens JHM(27). Lancet Oncol. 2018 Nov;19(11):1459-1467. doi: 10.1016/S1470-2045(18)30686-7. Epub 2018 Oct 19. (IF 35.4)
2. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Goetz MP(1), Sangkuhl K(2), Guchelaar HJ(3), Schwab M(4)(5)(6), Province M(7), Whirl-Carrillo M(2), Symmans WF(8), McLeod HL(9), Ratain MJ(10), Zembutsu H(11),Gaedigk A(12), van Schaik RH(13)(14), Ingle JN(1), Caudle KE(15), Klein TE(2). Clin Pharmacol Ther. 2018 Jan 31. doi: 10.1002/cpt.1007. [Epub ahead of print] (IF 6.3)
3. The Detection of Androgen Receptor Splice Variant 7 in Plasma-derived Exosomal RNA Strongly Predicts Resistance to Hormonal Therapy in Metastatic Prostate Cancer Patients. Del Re M(1), Biasco E(2), Crucitta S(3), Derosa L(2), Rofi E(3), Orlandini C(2),Miccoli M(4), Galli L(2), Falcone A(2), Jenster GW(5), van Schaik RH(6), Danesi R(3). Eur Urol. 2017 Apr;71(4):680-687. doi: 10.1016/j.eururo.2016.08.012. Epub 2016 Oct 10. (IF 17.3)
4. CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Elens L, Nieuweboer A, Clarke SJ, Charles KA, de Graan AJ, Haufroid V, Mathijssen RH, van Schaik RH.. Pharmacogenomics. 2013 Jan;14(2):137-49. doi: 10.2217/pgs.12.202. (IF: 4.0)
5. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up.. Schröder FH(1), Hugosson J(2), Roobol MJ(3), Tammela TL(4), Zappa M(5), Nelen V(6), Kwiatkowski M(7), Lujan M(8), Määttänen L(9), Lilja H(10), Denis LJ(11), Recker F(12), Paez A(13), Bangma CH(3), Carlsson S(14), Puliti D(5), Villers A(15), Rebillard X(16), Hakama M(17), Stenman UH(18), Kujala P(19), Taari K(20),Aus G(21), Huber A(22), van der Kwast TH(23), van Schaik RH(24), de Koning HJ(25), Moss SM(26), Auvinen A(27); for the ERSPC Investigators. Lancet. 2014 Aug 6. pii: S0140-6736(14)60525-0. doi: 10.1016/S0140-6736(14)60525-0. [Epub ahead of print] (IF 59.1)
Collaborations
Collaborations within Erasmus MC:
Hospital Pharmacy, Medical Oncology, Internal Medicine, Psychiatry, Urology, Children’s Surgery, Cardiology
Collaborations outside of Erasmus MC
International:
University of Pisa – Prof Romano Danesi, Dr Marzia del Re
University of Estonia – Prof Lili Milani
Georgetown University – Prof John van den Anker
University of Patras – Prof George Patrinos
Thrace University Alexandropoulis – Prof Vangelis Manolopoulos
National:
CZ Insurrances
STAR-SHL – Marieke van Schaik, Wim Rutten
LUMC – Prof Henk-Jan Guchelaar, Dr Jesse Swen
Radboud University –
UMC Utrecht – Dr Maarten ten Berg, Dr Vera Deneer
Amsterdam UMC – Prof Robert de Jonge
NKI Amsterdam – Dr Daan van den Broek, Prof Gerrit Meijer
UMC Groningen – Prof Ed Schuuring
Our team
Ron van Schaik, Prof. Dr. – PI
Maja Matic, Dr. – Post Doc
Mirjam de With – PhD student
Evert de Jonge – research technician
Samira el Bouazzaoui – research technician
Iris Smits - research technician
Tessa Mulder - research technician
Sanne Suijker - resident
Contact us
r.vanschaik@erasmusmc.nl